<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">rpmj</journal-id><journal-title-group><journal-title xml:lang="ru">Research'n Practical Medicine Journal</journal-title><trans-title-group xml:lang="en"><trans-title>Research and Practical Medicine Journal</trans-title></trans-title-group></journal-title-group><issn pub-type="epub">2410-1893</issn><publisher><publisher-name>"QUASAR", LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.17709/2409-2231-2020-7-1-4</article-id><article-id custom-type="elpub" pub-id-type="custom">rpmj-498</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>Оригинальные статьи. Урология и андрология</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>Original Articles. Urology</subject></subj-group></article-categories><title-group><article-title>Эпидемиологические аспекты сочетания нефролитиаза и хронических заболеваний сердечно-сосудистой системы</article-title><trans-title-group xml:lang="en"><trans-title>Epidemiological aspects of nephrolithiasis and chronic diseases of the cardiovascular system combination</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8335-030X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Роюк</surname><given-names>Р. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Royuk</surname><given-names>R. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Роюк Руслан Валерьевич – к.м.н., начальник урологического отделения филиала №1 </p><p>Адрес: 107014, г. Москва, ул. Поперечный просек, д. 17 </p><p>SPIN: 5478-9593</p></bio><bio xml:lang="en"><p>Ruslan V. Royuk – Cand. Sci. (Med.), head of the urological department of branch No. 1 </p><p>SPIN: 5478-9593</p></bio><email xlink:type="simple">royuk@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4543-1480</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Яровой</surname><given-names>С. К.</given-names></name><name name-style="western" xml:lang="en"><surname>Yarovoy</surname><given-names>S. K.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Яровой Сергей Константинович – д.м.н., главный научный сотрудник, врач клинический фармаколог </p><p>врач-клинический фармаколог </p><p>SPIN: 2848-7750</p></bio><bio xml:lang="en"><p>Sergei K. Yarovoy – Dr. Sci. (Med.), chief scientific officer, a physician and clinical pharmacologist </p><p>physician-clinical pharmacologist </p><p>SPIN: 2848- 7750</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Гусева</surname><given-names>Н. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Guseva</surname><given-names>N. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Гусева Надежда Андреевна – заведующая терапевтическим отделением</p></bio><bio xml:lang="en"><p>Nadezhda A. Guseva – head of the therapeutic department</p></bio><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Восканян</surname><given-names>Ш. Л.</given-names></name><name name-style="western" xml:lang="en"><surname>Voskanyan</surname><given-names>Sh. L.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Восканян Шушанна Левоновна – врач-эпидемиолог </p><p>SPIN: 5585-7630</p></bio><bio xml:lang="en"><p>Shushanna L. Voskanyan – physician epidemiologist </p><p>SPIN: 5585-7630</p></bio><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Роюк</surname><given-names>В. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Royuk</surname><given-names>V. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Роюк Валерий Валериевич – к.м.н., врач-методист </p><p>SPIN: 7535-4008</p></bio><bio xml:lang="en"><p>Valerii V. Royuk – Cand. Sci. (Med.), physician-methodist </p><p>SPIN: 7535-4008</p></bio><xref ref-type="aff" rid="aff-4"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Родин</surname><given-names>Д. Б.</given-names></name><name name-style="western" xml:lang="en"><surname>Rodin</surname><given-names>D. B.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Родин Дмитрий Борисович – начальник урологического центра филиала №1</p></bio><bio xml:lang="en"><p>Dmitrii B. Rodin – head of the urological center of branch No. 1</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБУ «Главный военный клинический госпиталь им. академика Н.Н.Бурденко» Министерства обороны Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>N.N.Burdenko Academician Main Military Clinical Hospital</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>НИИ урологии и интервенционной радиологии им. Н.А.Лопаткина – филиал ФГБУ «НМИЦ радиологии» Министерства здравоохранения Российской Федерации; &#13;
ГБУЗ «Городская клиническая больница им. Д.Д.Плетнёва Департамента здравоохранения города Москвы»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>N.A.Lopatkin Scientific Research Institute of Urology and Interventional Radiology – branch of the National Medical Research Radiologiсal Center; &#13;
City Clinical Hospital. D.D.Pletnev of the Moscow city health Department,</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>ГБУЗ «Городская клиническая больница им. Д.Д.Плетнёва Департамента здравоохранения города Москвы»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>City Clinical Hospital. D.D.Pletnev of the Moscow city health Department,</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-4"><aff xml:lang="ru"><institution>ГБУЗ МО «Красногорская городская больница №1»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Krasnogorsk City Hospital No.1</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2020</year></pub-date><pub-date pub-type="epub"><day>12</day><month>03</month><year>2020</year></pub-date><volume>7</volume><issue>1</issue><fpage>38</fpage><lpage>47</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Роюк Р.В., Яровой С.К., Гусева Н.А., Восканян Ш.Л., Роюк В.В., Родин Д.Б., 2020</copyright-statement><copyright-year>2020</copyright-year><copyright-holder xml:lang="ru">Роюк Р.В., Яровой С.К., Гусева Н.А., Восканян Ш.Л., Роюк В.В., Родин Д.Б.</copyright-holder><copyright-holder xml:lang="en">Royuk R.V., Yarovoy S.K., Guseva N.A., Voskanyan S.L., Royuk V.V., Rodin D.B.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.rpmj.ru/rpmj/article/view/498">https://www.rpmj.ru/rpmj/article/view/498</self-uri><abstract><sec><title>Цель исследования</title><p>Цель исследования. Проанализировать распространенность и особенности сердечно-сосудистых заболеваний (ССЗ) у пациентов с впервые выявленной мочекаменной болезнью (МКБ).</p></sec><sec><title>Материалы и методы</title><p>Материалы и методы. Проведен ретроспективный анализ историй болезни 2311 больных с МКБ, лечившихся в урологических отделениях филиала № 1 ГВКГ им. Н.Н. Бурденко (n=1487) и ГБУЗ МО «Красногорская городская больница № 1» (n=824) в период с 2009 по 2018 гг. В 67,6% случаев (1562 пациента) диагноз МКБ был установлен впервые при поступлении. Изолированная МКБ была зафиксирована у 676 (43,3%), еще у 154 (9,8%) нефролитаз сочетался с различными вариантами ССЗ и сахарным диабетом. Из 732 респондентов с МКБ и сопутствующими ССЗ были сформированы 3 группы, в первую (I; n=363) из которых были включены пациенты с гипертонической болезнью (ГБ) и артериальной гипертензией (АГ); II группа (n=79) состояла из пациентов с изолированной ишемической болезнью сердца (ИБС). В III группу вошли 290 больных, у которых МКБ сочеталась с ГБ+АГ+ИБС. Стадии ГБ и степень выраженности АГ) приведены в соответствии с рекомендациями Всероссийского научного общества кардиологов (2004). Стадии хронической сердечной недостаточности (ХСН) определяли в соответствии с классификацией NYHA (New York Heart Association – Нью-Йоркская ассоциация кардиологов). Функциональный класс (ФК) стабильной стенокардии определяли в соответствии с классификацией Канадской ассоциации кардиологов (1970, 1976). Полученные данные анализировали, используя методы описательной статистики.</p></sec><sec><title>Результаты</title><p>Результаты. Возраст пациентов в среднем был равен 65,4±3,27; 78% общего количества больных составляли мужчины. В экстренном порядке в стационары поступили 30,9% из I группы, 27,6% – из II, и 31,3% – из III группы. В I группе чаще фиксировали ГБ I + АГ I (32,5% случаев) и ГБ II + АГ II (40,2%). Во II группе стенокардия напряжения зафиксирована в 30 (38%) случаях. ХСН имела место у 153 (20,9%) пациентов; чаще всего она встречалась у пациентов III группы – в 102 (35,2%) случаях. В целом по выборке преобладала ХСН I и II степеней – у 88 (12%) и 57 (7,9%) пациентов. Камни в почках были обнаружены у 59,4% пациентов, в мочеточниках – у 30,9%, и в почках, и в мочеточниках – у 9,9%. Доля пациентов с коралловидными камнями почек составила 3,4% от общей выборки. Средние размеры камней в почках пациентов с ХСН – 9,2–11,8 мм отличались от таковых в общей выборке – 6,9–9,5 мм.</p></sec><sec><title>Заключение</title><p>Заключение. За период наблюдения доля пациентов с впервые выявленной МКБ, осложненной ССЗ, выросла в 1,9 раза (16,7 против 31,7%). Зарегистрированная у 20,9% пациентов ХСН в 19,8% случаев была отнесена к I и II степени. Наличие хронических ССЗ, особенно осложненных ХСН, у пациентов с первые выявленным нефролитазом предполагает изменения алгоритмов метафилактики нефролитиаза (режим водной нагрузки, подбор диуретиков и антикоагулянтов).</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Purpose of the study</title><p>Purpose of the study. To analyze prevalence and characteristics of the cardiovascular diseases (CVD) in patients with urolithiasis, revealed for the first time</p></sec><sec><title>Materials and methods</title><p>Materials and methods. In a period between 2009 and 2018, was made a retrospective analysis of medical histories of 2311 patients with urolithiasis, which were treated in in the urology departments of the branch No. 1 of the MCHG named after N.N. Burdenko (n=1487) and GBUZ MO Krasnogorsk City Hospital No. 1 (n=824). In 67,6% of the cases (1562 patients) the diagnosis of urolithiasis was diagnosed for the first time on admission. Isolated urolithiasis was recorded in 676 cases (43,3%), in other 154 cases (9,8%) nephrolithiasis was combined with different variants of cardiovascular diseases (CVD) and diabetes. From 732 respondents with urolithiasis and associated cardiovascular diseases (CVD), were formed 3 groups, in the first group (I) were included patients (n=363) with hypertension and arterial hypertension: the second group (II; n=79) was formed from patients with isolated coronary heart disease. In the third group (III) were included 290 patients which had urolithiasis combined with hypertension, arterial hypertension and coronary heart disease. The stages of hypertension and degree of expression of arterial hypertension were given according to the recommendations of Russian science society of cardiology (2004). Stages of congestive heart failure were defined according to c NYHA (New York Heart Association) classification. Functional class of stable angina was defined according to Canadian Cardiovascular Society classification (1970,1976). The obtained data was analyzed using descriptive statistics methods.</p></sec><sec><title>Results</title><p>Results. Average age of patients was 65,4 +– 3,27; 78% of the patients were men. On an emergency basis were hospitalized 30,9% from group I, 27,6% from group 2, and 31,3% from group III. In group I more often were recorded hypertension I + arterial hypertension I (32,5%) and hypertension II + arterial hypertension II (40,2%). In group II effort angina was recorded in 30 cases (38%). Congestive heart failure occurred among 153 patients (20,9%); most often it occurred among patients from III – in 102 cases (35,2%). In the whole sample, congestive heart failure of I and II degrees prevailed – in 88 (12%) and 57 (7,9%) patients. Kidney stones were found in 59,4% of patients, in the ureters – in 30,9% of patients, in kidneys and in the ureters – in 9,9% of patients. Share of the patients with kidney stones in the shape of corals is 3,4% of the whole sample. Average sizes of kidney stones of the patients with congestive heart failure are 9,2–11,8 mm which is different from the sizes in whole sample – 6,9–9,5 mm.</p></sec><sec><title>Conclusion</title><p>Conclusion. During the observation period, share of the patients with first time revealed urolithiasis, complicated with the cardiovascular diseases (CVD) increased in 1,9 times (16,7 versus 31,7%). Congestive heart failure, which was registered in 20,9% of patients, was charged with I and II degrees. The presence chronic cardiovascular diseases (CVD), especially complicated by congestive heart failure in patients with first time revealed nephrolithiasis, implies changes in the algorithms of metaphylactic of nephrolithiasis (regime of water loads, selection of diuretics and anticoagulants).</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>артериальная гипертензия</kwd><kwd>атеросклероз</kwd><kwd>гипертоническая болезнь</kwd><kwd>ишемическая болезнь сердца</kwd><kwd>мочекаменная болезнь</kwd><kwd>хроническая сердечная недостаточность</kwd></kwd-group><kwd-group xml:lang="en"><kwd>arterial hypertension</kwd><kwd>atherosclerosis</kwd><kwd>hypertension</kwd><kwd>coronary heart disease</kwd><kwd>urolithiasis</kwd><kwd>congestive heart failure</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Борисов В.В., Дзеранов Н.К. Мочекаменная болезнь. Терапия больных камнями почек и мочеточников.М., 2011, 88 с.</mixed-citation><mixed-citation xml:lang="en">Borisov VV, Dzeranov NK. Urolithiasis disease. Therapy of patients with kidney and ureter stones.M., 2011, 88 p. (In Russian).</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Akoudad S, Szklo M, McAdams MA, Fulop T, Anderson CAM, Coresh J, et al. Correlates of kidney stone disease differ by race in a multi-ethnic middle-aged population: The ARIC study. Preventive Medicine. 2010 Nov 1; 51(5):416–420. https://doi.org/10.1016/j.ypmed.2010.08.011</mixed-citation><mixed-citation xml:lang="en">Akoudad S, Szklo M, McAdams MA, Fulop T, Anderson CAM, Coresh J, et al. Correlates of kidney stone disease differ by race in a multi-ethnic middle-aged population: The ARIC study. Preventive Medicine. 2010 Nov 1; 51 (5):416–420. https://doi.org/10.1016/j.ypmed.2010.08.011</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Аронов Д.М., Арабидзе Г. Г., Ахмеджанов Н.М., Балахонова Т.В., Бойцов С.А., Бубнова М. Г.идр. Диагностика икоррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Российские рекомендации (V пересмотр). Российский кардиологический журнал. 2012; 17(4 S1):2–32.</mixed-citation><mixed-citation xml:lang="en">Aronov DM, Arabidze GG, Akhmedzhanov NM, Balakhonova TV, Boitsov SA, Bubnova MG, et al. Diagnostics and correction of disorders of lipid metabolism for the prevention and treatment of atherosclerosis. Russian recommendations (v revision). Russian Journal of Cardiology. 2012; 17 (4 S1):2–32. (In Russian).</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Fabris A, Ferraro PM, Comellato G, Caletti C, Fantin F, Zaza G, et al. The relationship between calcium kidney stones, arterial stiffness and bone density: unraveling the stone-bonevessel liaison. J Nephrol. 2015 Oct; 28(5):549–555. https://doi.org/10.1007/s40620–014–0146–0</mixed-citation><mixed-citation xml:lang="en">Fabris A, Ferraro PM, Comellato G, Caletti C, Fantin F, Zaza G, et al. The relationship between calcium kidney stones, arterial stiffness and bone density: unraveling the stone-bonevessel liaison. J Nephrol. 2015 Oct; 28 (5):549–555. https://doi.org/10.1007/s40620–014–0146–0</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Nakashima Y, Wight TN, Sueishi K. Early atherosclerosis in humans: role of diffuse intimal thickening and extracellular matrix proteoglycans. Cardiovasc Res. 2008 Jul 1; 79(1):14–23. https://doi.org/10.1093/cvr/cvn099</mixed-citation><mixed-citation xml:lang="en">Nakashima Y, Wight TN, Sueishi K. Early atherosclerosis in humans: role of diffuse intimal thickening and extracellular matrix proteoglycans. Cardiovasc Res. 2008 Jul 1; 79 (1):14–23. https://doi.org/10.1093/cvr/cvn099</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Shavit L, Girfoglio D, Vijay V, Goldsmith D, Ferraro PM, Moochhala SH, et al. Vascular calcification and bone mineral density in recurrent kidney stone formers. Clin J Am Soc Nephrol. 2015 Feb 6; 10(2):278–285. https://doi.org/10.2215/CJN.06030614</mixed-citation><mixed-citation xml:lang="en">Shavit L, Girfoglio D, Vijay V, Goldsmith D, Ferraro PM, Moochhala SH, et al. Vascular calcification and bone mineral density in recurrent kidney stone formers. Clin J Am Soc Nephrol. 2015 Feb 6; 10 (2):278–285. https://doi.org/10.2215/CJN.06030614</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Hsi RS, Spieker AJ, Stoller ML, Jacobs DR, Reiner AP, McClelland RL, et al. Coronary Artery Calcium Score and Association with Recurrent Nephrolithiasis: The Multi-Ethnic Study of Atherosclerosis. Journal of Urology. 2016 Apr 1; 195(4 Part 1):971–976. https://doi.org/10.1016/j.juro.2015.10.001</mixed-citation><mixed-citation xml:lang="en">Hsi RS, Spieker AJ, Stoller ML, Jacobs DR, Reiner AP, McClelland RL, et al. Coronary Artery Calcium Score and Association with Recurrent Nephrolithiasis: The Multi-Ethnic Study of Atherosclerosis. Journal of Urology. 2016 Apr 1; 195 (4 Part 1):971–976. https://doi.org/10.1016/j.juro.2015.10.001</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Mackness MI, Durrington PN, Ayub A, Mackness B. Low serum paraoxonase: a risk factor for atherosclerotic disease? Chem Biol Interact. 1999 May 14; 119–120:389–397. https://doi.org/10.1016/s0009–2797(99)00050–2</mixed-citation><mixed-citation xml:lang="en">Mackness MI, Durrington PN, Ayub A, Mackness B. Low serum paraoxonase: a risk factor for atherosclerotic disease? Chem Biol Interact. 1999 May 14; 119–120:389–397. https://doi.org/10.1016/s0009–2797 (99)00050–2</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Aviram M. Atherosclerosis: cell biology and lipoproteins – paraoxonases protect against atherosclerosis and diabetes development. Curr Opin Lipidol. 2012 Apr; 23(2):169– 171. https://doi.org/10.1097/MOL.0b013e3283513594</mixed-citation><mixed-citation xml:lang="en">Aviram M. Atherosclerosis: cell biology and lipoproteins – paraoxonases protect against atherosclerosis and diabetes development. Curr Opin Lipidol. 2012 Apr; 23 (2):169– 171. https://doi.org/10.1097/MOL.0b013e3283513594</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Atar A, Gedikbasi A, Sonmezay E, Kiraz ZK, Abbasoglu S, Tasci AI, et al. Serum paraoxonase 1 gene polymorphism and enzyme activity in patients with urolithiasis. Renal Failure. 2016 Mar 15; 38(3):378–382. https://doi.org/10.3109/088602 2X.2015.1136872</mixed-citation><mixed-citation xml:lang="en">Atar A, Gedikbasi A, Sonmezay E, Kiraz ZK, Abbasoglu S, Tasci AI, et al. Serum paraoxonase 1 gene polymorphism and enzyme activity in patients with urolithiasis. Renal Failure. 2016 Mar 15; 38 (3):378–382. https://doi.org/10.3109/0886022X.2015.1136872</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Alexander RT, Hemmelgarn BR, Wiebe N, Bello A, Samuel S, Klarenbach SW, et al. Kidney stones and cardiovascular events: a cohort study. Clin J Am Soc Nephrol. 2014 Mar; 9(3):506–512. https://doi.org/10.2215/CJN.04960513</mixed-citation><mixed-citation xml:lang="en">Alexander RT, Hemmelgarn BR, Wiebe N, Bello A, Samuel S, Klarenbach SW, et al. Kidney stones and cardiovascular events: a cohort study. Clin J Am Soc Nephrol. 2014 Mar; 9 (3):506–512. https://doi.org/10.2215/CJN.04960513</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Ernandez T, Bonny O. [Kidney stone as a cardiovascular risk marker]. Rev Med Suisse. 2014 Sep 10; 10(441):1656–1660.</mixed-citation><mixed-citation xml:lang="en">Ernandez T, Bonny O. [Kidney stone as a cardiovascular risk marker]. Rev Med Suisse. 2014 Sep 10; 10 (441):1656–1660.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Skolarikos A, Straub M, Knoll T, Sarica K, Seitz C, Petřík A, et al. Metabolic evaluation and recurrence prevention for urinary stone patients: EAU guidelines. Eur Urol. 2015 Apr; 67(4):750– 763. https://doi.org/10.1016/j.eururo.2014.10.029</mixed-citation><mixed-citation xml:lang="en">Skolarikos A, Straub M, Knoll T, Sarica K, Seitz C, Petřík A, et al. Metabolic evaluation and recurrence prevention for urinary stone patients: EAU guidelines. Eur Urol. 2015 Apr; 67 (4):750– 763. https://doi.org/10.1016/j.eururo.2014.10.029</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Lin S K, Liu J M, Chang Y H, Ting Y T, Pang S T, Hsu R J, et al. Increased risk of endotracheal intubation and heart failure following acute myocardial infarction in patients with urolithiasis: a nationwide population-based study. Ther Clin Risk Manag. 2017; 13:245–253. https://doi.org/10.2147/TCRM.S123702</mixed-citation><mixed-citation xml:lang="en">Lin S K, Liu J M, Chang Y H, Ting Y T, Pang S T, Hsu R J, et al. Increased risk of endotracheal intubation and heart failure following acute myocardial infarction in patients with urolithiasis: a nationwide population-based study. Ther Clin Risk Manag. 2017; 13:245–253. https://doi.org/10.2147/TCRM.S123702</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Taylor ER, Stoller ML. Vascular theory of the formation of Randall plaques. Urolithiasis. 2015 Jan; 43 Suppl 1:41–45. https://doi.org/10.1007/s00240–014–0718–4</mixed-citation><mixed-citation xml:lang="en">Taylor ER, Stoller ML. Vascular theory of the formation of Randall plaques. Urolithiasis. 2015 Jan; 43 Suppl 1:41–45. https://doi.org/10.1007/s00240–014–0718–4</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Лиходед В. Г., Бондаренко В.М., Гинцбург А.Л. Экзогенные и эндогенные факторы в патогенезе атеросклероза. Рецепторная теория атерогенеза. Российский кардиологический журнал. 2010; 15(2):92–96.</mixed-citation><mixed-citation xml:lang="en">Likhoded VG, Bondarenko VM, Gintsburg AL. Exogenous and endogenous factors in atherosclerosis pathogenesis. Receptor theory of atherogenesis. Russian Journal of Cardiology. 2010; 15 (2):92–96. (In Russian).</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Воробьева Е.Н., Симонова Г.И., Воробьев Р.И., Лещенко И.Ж. Свободно-радикальное окисление и атеросклероз. Атеросклероз. 2010; 6(2):20–27.</mixed-citation><mixed-citation xml:lang="en">Vorob'eva EN, Simonova GI, Vorob'ev RI, Leshchenko IZh. Free-radical oxidation and atherosclerosis. Atherosclerosis. 2010; 6 (2):20–27. (In Russian).</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Ахминеева А. Х. Эндотелиальная дисфункция и оксидативный стресс в развитии респираторно- кардиальной коморбидности: Диссертация д.м.н. Астрахань, 2015.</mixed-citation><mixed-citation xml:lang="en">Akhmineeva, A.Kh. Endothelial dysfunction and oxidative stress in the development of respiratory-cardial comorbidity: the Dissertation of the doctor of medical sciences Astrakhan, 2015. (In Russian).</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Просянников М.Ю., Анохин Н.В., Голованов С.А., Кирпатовский В.И., Сивков А.В., Константинова О.В. идр. Мочекаменная болезнь и сердечно-сосудистые заболевания: только статистическая связь или общность патогенетических механизмов? Экспериментальная и клиническая урология. 2018;(3):34–41.</mixed-citation><mixed-citation xml:lang="en">Prosyannikov MYu, Anokhin NV, Golovanov SA, Kirpatovskii VI, Sivkov AV, Konstantinova OV, et al. Urolithiasis and cardiovascular diseases: only a statistical link or a common pathogenetic mechanism? Experimental and Clinical Urology. 2018; (3):34–41. (In Russian).</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Батько А.Б. Артериальная гипертензия и мочекаменная болезнь: патогенетические параллели. Terra Medica. 2013; 1(71):44–48.</mixed-citation><mixed-citation xml:lang="en">Bat'ko AB. Hypertension and urolithiasis: pathogenetic parallels. Terra Medica. 2013; 1 (71):44–48. (In Russian).</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Чазова И.Е, Жернакова Ю.В. Диагностика и лечение артериальной гипертонии. Системные гипертензии. 2019; 16(1):6–31. https://doi.org/10.26442/2075082X.2019.1.190179</mixed-citation><mixed-citation xml:lang="en">Chazova IE, Zhernakova YuV. Diagnosis and treatment of arterial hypertension. Systemic Hypertension. 2019; 16 (1):6–31. (In Russian). https://doi.org/10.26442/2075082X.2019.1.190179</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
